


217836US0PCT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Stefano BONGRANI, et al.

New US PCT application based on PCT/EP00/07184

GAU:

FILED:

SERIAL NO:

Herewith

EXAMINER:

FOR:

2-AMINOTETRALIN DERIVATIVES FOR THE THERAPY OF GLAUCOMA

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☐ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND. MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No.

24,618


Surinder Sachar

Registration No.

34,423

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 10/01)





23_{sheet} 2707_{of}

				ATTY DOCKET NO.		SERIANDO ZO 9 7 16		
Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE			217836US0PCT		New US PCT/application based on PCT/EP00/07184			
LICTOF	محدد	DENOTE CITED DV ADD	LICANT	APPLICANT				
LIST OF	KEFER	RENCES CITED BY APP	LICANT	Stefano BONGRAN				
				FILING DATE Herewith		GROUP		
U.S. PATENT DOCUMENTS								
EVAMINED DOCUMENT SUB SUINC DATE								
INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	IF APPROPRIATE	
	AA	5 236 907	08/17/93	Ryuzo UENO et al.				
	AB							
	AC							
	AD							
	AE							
	AF							
	AG							
	AH							
	Al							
	AJ							
	AK							
	AL							
	AM							
	AN							
FOREIGN PATENT DOCUMENTS								
		DOCUMENT		TRANSLATION		TRANSLATION		
		NUMBER	DATE	COUNTRY		YES		
	AO	2 123 410	02/01/84	GB			No	
	AP	96 29065	09/26/96	wo			No	
	AQ	0 009 702	04/16/80	EP			No	
	AR							
	AS							
	AT							
	AU							
	AV		1					
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)								
	AW	Carmine MORISCO et al.: "Hemodynamic effects of graded oral doses of a new dopaminergic analogue CHF 1035 in patients with congestive heart failure" JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, no. SPEC. ISSUE, page 128A 1995						
	AX							
	AY							
	AZ				Addi	tional Refe	rences sheet(s) attached	
Examiner					Date Cor	Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								